Literature DB >> 1327283

Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl.

P Laneuville1, G Sun, M Timm, M Vekemans.   

Abstract

Current evidence suggests that the expression of the tyrosine kinase p210bcr/abl in chronic myelogenous leukemia (CML) may directly induce the initial phase of granulocytic hyperplasia. However, the dysregulation of additional genes appears to be required for transition to the acute leukemic phase, as inferred by the appearance of recurrent secondary cytogenetic abnormalities in the majority of patients. To determine whether the expression of p210bcr/abl alone is responsible for this genetic instability, we introduced and expressed the bcr/abl gene from a retroviral vector in a clone of the interleukin-3 (IL-3) dependent myeloblastic 32D C13(G) cell line. Clonal and polyclonal cells transformed to IL-3 independent growth were observed for a period extending up to 6 months for changes in the expression of p210bcr/abl, cell proliferation, inhibition by prostaglandin E1 (PGE1), forskolin, and cyclic adenosine monophosphate (cAMP) analogues, regulation of the cell cycle, and karyotype. Whereas the properties of control vector infected 32D C13(G)' cells remained stable over time, cells expressing p210bcr/abl were phenotypically unstable. In cells expressing p210bcr/abl, we observed selective modulation of p210bcr/abl mRNA and protein expression, evolution from partial to full abrogation of IL-3 dependence, reduced serum requirements, increased cell proliferation, decreased inhibition by PGE1 and cAMP analogues, and the appearance of new structural and numerical chromosomal abnormalities with successive cell passages. These results indicate that expression of p210bcr/abl can directly predispose 32D C13(G)' cells to genetic instability, promotes the emergence of clones with an increased proliferative advantage, and may represent an in vitro model suitable for the study of mechanisms underlying progression to the acute leukemic phase in CML.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327283

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Bcr/Abl expression stimulates integrin function in hematopoietic cell lines.

Authors:  G Bazzoni; N Carlesso; J D Griffin; M E Hemler
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

Review 2.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

3.  Presence of P210bcrabl is associated with decreased expression of a beta chemokine C10 gene in a P210bcrabl-positive myeloid leukemia cell line.

Authors:  C M Lane; X Y Guo; L H Macaluso; K C Yung; A B Deisseroth
Journal:  Mol Med       Date:  1999-01       Impact factor: 6.354

4.  Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.

Authors:  D B Zimonjic; J L Pollock; P Westervelt; N C Popescu; T J Ley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

Review 5.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

6.  The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.

Authors:  Keiko Okuda; Yuko Sato; Yoshiaki Sonoda; James D Griffin
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 7.  Biotherapy of chronic myelogenous leukemia.

Authors:  W E Aulitzky; C Peschel; F Schneller; C Huber
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

8.  BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Authors:  Mateusz Koptyra; Rafal Falinski; Michal O Nowicki; Tomasz Stoklosa; Ireneusz Majsterek; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

9.  BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold.

Authors:  J Dierov; P V Sanchez; B A Burke; H Padilla-Nash; M E Putt; T Ried; M Carroll
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

10.  A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells.

Authors:  J H Kabarowski; P B Allen; L M Wiedemann
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.